Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Cellectis S.A. (CLLS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
7.29-0.04 (-0.55%)
At close: 04:00PM EST
7.29 0.00 (0.00%)
After hours: 04:00PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close7.33
Open7.22
Bid7.04 x 1200
Ask7.57 x 800
Day's Range7.03 - 7.35
52 Week Range7.03 - 34.71
Volume241,926
Avg. Volume206,285
Market Cap346.173M
Beta (5Y Monthly)2.20
PE Ratio (TTM)N/A
EPS (TTM)-2.92
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est25.80
  • GlobeNewswire

    Monthly information on share capital and company voting rights

    (Article 223-16 of General Regulation of the French financial markets authority)NEW YORK, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of shares in the capitalTotal number of voting rights12/31/202145,484,81051,085,782 About Cellectis Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Cellectis utilizes an allogeneic approach for CAR-T immunoth

  • Zacks

    Allogene (ALLO) Clinical Hold on CAR-T Studies Removed by FDA

    The FDA removes the hold on Allogene's (ALLO) clinical studies evaluating AlloCAR T therapy candidates after investigations confirmed that there is no chromosomal abnormality in its candidates.

  • GlobeNewswire

    Cellectis’ Licensed Partner, Allogene Therapeutics, Announces Removal of FDA Clinical Hold on their Clinical Trials

    • Allogene reported that Chromosomal Abnormality Was Not the Result of TALEN® Gene Editing or Allogene’s Manufacturing Process • Allogene to Initiate a Phase 2 Pivotal Clinical Trial of ALLO-501A in Relapsed/Refractory Large B-cell Lymphoma Mid-year 2022 Pending FDA Discussion NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapie

Advertisement
Advertisement